HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%

MT Newswires Live

2024-11-22

HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.

The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.

After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.

CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.

The company's shares were down by 3% in recent trading.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2485284990"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485284990\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485284990?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 15:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485284990","market":"fut","top_or_hot":-1,"title":"HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%","media":"MT Newswires Live","content":"<html><body><p> HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.</p><p>The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.</p><p>After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.</p><p>CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.</p><p>The company's shares were down by 3% in recent trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-11-22 15:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p> HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.</p><p>The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.</p><p>After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.</p><p>CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.</p><p>The company's shares were down by 3% in recent trading.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485284990","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485284990","pubTimestamp":1732260110,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HUTCHMED   FRUZAQLA , its metastatic colorectal cancer  drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.After approval from Japan's Ministry of Health, FRUZAQLA became the first oral targeted therapy for metastatic colorectal cancer  in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.The company's shares were down by 3% in recent trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","LU0266512127.USD":"摩根大通环球自然资源 A(acc)","BK1191":"制药","LU0456854461.SGD":"JPMorgan Funds - Global Natural Resources A (acc) SGD","BK4213":"石油与天然气的勘探与生产","00013":"和黄医药","BK1587":"次新股","CRC":"加州资源"},"translate_title":"和黄医药（中国）将与武田在日本推出口服结直肠癌药物；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"CRC":1},"content_text":"HUTCHMED (China) (HKG:0013) FRUZAQLA (fruquintinib), its metastatic colorectal cancer (CRC) drug, will be launched in Japan by partner Takeda, according to a Friday filing with the Hong Kong bourse.The company will receive a milestone payment after the launch, as per the filing, without mentioning specifics.After approval from Japan's Ministry of Health, FRUZAQLA(r) became the first oral targeted therapy for metastatic colorectal cancer (CRC) in over a decade. The drug is for patients with advanced CRC who are unresponsive to chemotherapy.CRC remains Japan's most common cancer, with 161,000 new cases and 54,000 deaths projected in 2023, the filing added.The company's shares were down by 3% in recent trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1}}}